The Neuropsychiatric Drug Development Summit is the definitive meeting for biopharma leaders shaping the future of psychiatric R&D. At a time of renewed momentum in neuropsychiatry, this summit brings together senior decision‑makers to redefine how the industry translates science into successful, patient‑centred therapies.

Across discovery, translational science, and clinical development, the agenda showcases the most promising advances in the field — from psychedelics, muscarinics, orexins, and novel neuroplasticity approaches to cutting‑edge translational tools such as EEG, digital and speech biomarkers, sleep endpoints, and smarter patient stratification. Attendees will gain practical insights into overcoming placebo response, heterogeneity, and late‑stage failure through biology‑driven, regulatory‑ready strategies.

Designed for meaningful connection and collaboration, the summit offers an intimate, highly interactive environment to exchange data, challenge assumptions, and build partnerships with peers tackling depression, schizophrenia, bipolar disorder, anxiety, PTSD, and addiction. Join the global community accelerating the next era of precision psychiatry.

Find out more today – https://ter.li/rt2cakk3